CORMEDIX INC. Total Liabilities and Equity
CORMEDIX INC. (CRMD) had Total Liabilities and Equity of $904.05 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $904.05M.
- 2026-03-31: Liabilities and Equity $815.64M.
- 2025-12-31: Liabilities and Equity $826.14M.
- 2025-09-30: Liabilities and Equity $750.86M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $904.05M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $815.64M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $826.14M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $750.86M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $252.60M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $149.58M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $118.85M 10-K · filed 2026-03-05 | $118.85M 10-K · filed 2025-03-25 |
| 2024-09-30 | $77.59M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $57.73M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $68.02M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $82.06M 10-K · filed 2025-03-25 | |
| 2023-09-30 | $91.43M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $57.03M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $59.23M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $62.04M 10-K · filed 2024-03-12 | |
| 2022-09-30 | $62.08M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $67.75M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $64.93M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $68.95M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $75.39M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $80.86M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $84.26M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $49.31M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $40.02M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $24.24M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $27.40M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $29.48M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $33.72M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $27.56M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $27.31M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $18.83M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $8.05M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $5.93M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $9.61M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $13.45M 10-K · filed 2019-05-29 | |
| 2017-09-30 | $13.93M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $21.16M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $14.93M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $21.91M 10-K · filed 2018-03-19 | |
| 2016-09-30 | $28.84M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $31.21M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $33.61M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $37.10M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $39.31M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $38.80M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $9.75M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $5.10M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $6.85M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $8.26M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $9.76M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $2.97M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $1.04M 10-Q/A · filed 2014-03-04 | |
| 2013-06-30 | $395.08K 10-Q/A · filed 2014-03-04 | |
| 2013-03-31 | $967.65K 10-Q/A · filed 2014-03-04 | |
| 2012-12-31 | $1.15M 10-K · filed 2014-03-31 | |
| 2012-09-30 | $1.26M 10-Q/A · filed 2013-03-27 | |
| 2012-06-30 | $1.04M 10-Q/A · filed 2012-09-06 | |
| 2012-03-31 | $2.04M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $2.56M 10-K/A · filed 2014-03-04 | |
| 2011-09-30 | $3.03M 10-Q · filed 2011-11-10 | |
| 2011-06-30 | $4.95M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $8.85M 10-K/A · filed 2012-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |